is...Long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, we'll spotted. 👍️
#dcvax #allsolidtumors $nwbo #gbm #TissueAgnostic #PrecisionMedicine
— Peter Davis (@peter_brit) January 27, 2024
UK has a terrible record for brain cancer survival (22/29), the submission for approval of DCVAXĀ®-L could not come at a better time.https://t.co/k9FcN2nnNQ pic.twitter.com/KeKpII6RM6
#dcvax #allsolidtumors $nwbo #gbm #TissueAgnostic #PrecisionMedicine
— Peter Davis (@peter_brit) January 27, 2024
āILAP enabled regular and open dialogue with NICE which was crucial in ensuring patients were able to access this medicine as early as possible.āhttps://t.co/PuPzJBFXoH pic.twitter.com/UwMHy60Pd1
#dcvax #allsolidtumors $nwbo #gbm #TissueAgnostic #PrecisionMedicine
— Peter Davis (@peter_brit) January 27, 2024
Curious About Cancer Care? These Are Breakthroughs and Trends in Immunotherapy
January 18, 2024
Cancer immunotherapy is the most innovative and forward-thinking form of cancer treatment available to patientsā¦ pic.twitter.com/T0NcpDPbIO
#dcvax #allsolidtumors $nwbo #gbm #TissueAgnostic #PrecisionMedicine
— Peter Davis (@peter_brit) January 26, 2024
For years, brain tumours have remained notoriously difficult to diagnose. They affect hundreds of thousands of people worldwide each year, and kill more children and adults under the age of 40 in the UK thanā¦ pic.twitter.com/Dfk54PAJOG
#dcvax #allsolidtumors $nwbo #gbm #TissueAgnostic #PrecisionMedicine
— Peter Davis (@peter_brit) January 25, 2024
11th Neuro-Oncology Brain Tumor Symposium 2024
Friday, January 26, 2024
CME/CNE-accredited
patient & caregiver program
7:30 am - 4:00 pm EST
Progress in āThe War on Cancerā Innovation and Scientificā¦ pic.twitter.com/4ltqoUb72t
Anybody have full access ?
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 20, 2024
Impact of tissue-agnostic approvals on management of primary brain tumors
Tissue-agnostic approvals, based on basket trials of multiple tumor histology, permit biomarker-driven targeting of specific shared molecular alterations, regardless ofā¦ https://t.co/CfqRoXNJj6
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 18, 2024
Another lovely story of a long-term DCVaxĀ® survivor. Nigel French was diagnosed in 2015.
One patient in the 331-person multicentre global study lived for more than eight years after receiving DCVax. In Britain, 53-year-old Nigel French isā¦ pic.twitter.com/z3mH4GI9WX
"Itās going to be critical for mRNA type treatments"
These approaches however, are certainly not limited to use with mRNA type treatments, This could improve the efficacy and safety of DCVax and other personalized cancer vaccines. The article does give the following examples:-
"More recently, personalized vaccinations in the form of mRNA, peptides, or peptide-loaded antigen presenting cells (APCs) have been shown to be safe, immunogenic and capable of generating durable clinical response"
However, he article author's statement:-
"Cutting edge approaches, that leverage the computational tools and machine learning algorithms, have been developed recently offering new possibilities for understanding immune responses and developing personalized immunotherapies. Overall, these innovative tools, in combination with experimental data, pave the way for more effective and tailored immunotherapeutic approaches, offering valuable insights for personalized immunotherapies"
is just as relevant for DCVax and other personalzed immunotherapies as it is for mRNA treatments.
Introducing: The first-ever GLIOBLASTOMA SUMMIT.
— Glioblastoma Research Organization (@glioblastomaorg) January 16, 2024
Join us in Miami, FL on November 1-3, 2024 at Sacred Space Miami for 3 days of connecting with the glioblastoma community.
For inquiries email us at contact@gbmresearch.org pic.twitter.com/zhrUbwR5dm
#dcvax #allsolidtumors $nwbo #gbm @glioblastomaorg
— Peter Davis (@peter_brit) January 18, 2024
So sad.
On 21st December 2023. Northwest Biotherapeutics submitted a Marketing Authorization Application in the UK for DCVaxĀ®-L. Northwest Biotherapeutics personalized cancer vaccine treats both newly-diagnosed and recurrentā¦ pic.twitter.com/xpp4JLV91L
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 18, 2024
Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy
2023 Dec 12.
"Cutting edge approaches, that leverage the computational tools and machine learning algorithms, have been developedā¦ pic.twitter.com/RLmHZTBKzk
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 18, 2024
Historical perspective and future directions: computational science in immuno-oncology
First published January 8, 2024.
"Additional immuno-oncology approaches, including adoptive cell transfer (ACT) therapies and cancer vaccines, also holdā¦
#dcvax #allsolidtumors $nwbo #gbm https://t.co/M9mkQhhgnx
— Peter Davis (@peter_brit) January 17, 2024
#dcvax #allsolidtumors $nwbo #gbm @ImmortaBio
— Peter Davis (@peter_brit) January 17, 2024
"Many times we dont think of cells in their in vivo context ā¦here is finding that sheer stress induces DC activation. $nwbo are leading the clinical implementation of dendritic cells" https://t.co/Jse4ZiXk4R pic.twitter.com/aAII6xFToR
#dcvax #allsolidtumors $nwbo #gbm @ImmortaBio
— Peter Davis (@peter_brit) January 17, 2024
"Liver X Receptor (LXR) blocks dendritic cell maturationā¦if you want to supercharge $nwbo DC silence LXR" https://t.co/VNVojp7Gls pic.twitter.com/mufT7gcq3r
#dcvax #allsolidtumors $nwbo #gbm https://t.co/TxAmtkzbNw
— Peter Davis (@peter_brit) January 18, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 18, 2024
A Cancer Journal for Clinicians
ARTICLE
Cancer statistics, 2024https://t.co/KLFm7Cosxf pic.twitter.com/EVNv7muBI2
#dcvax #allsolidtumors $nwbo #gbm https://t.co/SxDHmkeDkJ
— Peter Davis (@peter_brit) January 18, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 17, 2024
Please help us to extend Danielleās life
DCVax-L is a type of immunotherapy known as a dendritic cell vaccine. Developed by Northwest Biotherapeutics DCVax-L is a personalised vaccine made from each patientās own dendritic cells ā a type ofā¦ pic.twitter.com/2NBfSXK3Oz
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 17, 2024
Experts Forecast 2024, Part 1: Advances in Cancer Vaccines
January 8, 2024 by Neha J. Pancholi, PhD
2024 is here, and there is so much on the yearās agendaāa total solar eclipse over parts of North America; the Summer Olympics in Paris; theā¦ pic.twitter.com/ZaO3cPFIlU
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 17, 2024
Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma
31 October 2023
"Recently, in 2023, Liau et al. revealed the results from a large Phase III trialā¦ pic.twitter.com/vVsPx65Ucn
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 17, 2024
Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine
Published: 06 January 2024
"In a recent Phase 3 prospective externally controlled non-randomized trial, the overall survival rate (OS) of GBM patients whoā¦ pic.twitter.com/PgFsP8TMzl
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 17, 2024
Glioblastoma Immunotherapy: New Hope in Brain Cancer Treatment
January 16, 2024
"Despite surgery, radiation and chemotherapy, recurrence remains almost inevitable without additional interventions combatting microscopic glioblastoma foci.ā¦ https://t.co/okoaVTOEZ8
Thanks to the October 2023 published CBTRUS Statistical Report: Primary Brain and Other Central Nervous System (CNS) Tumors Diagnosed in the United States in 2016-2020, weāre staying current on CNS tumor trends.
— Glioblastoma Research Organization (@glioblastomaorg) January 16, 2024
Source: Neuro-Oncology, https://t.co/0Yg6rx9rEN pic.twitter.com/MnTaxCjelK
#dcvax #allsolidtumors $nwbo #gbm https://t.co/fjSTR4KM4M
— Peter Davis (@peter_brit) January 17, 2024
#dcvax #allsolidtumors $nwbo #gbm https://t.co/OXcf2YVBAR
— Peter Davis (@peter_brit) January 17, 2024
#dcvax #allsolidtumors $nwbo #gbm https://t.co/8XP3BSYuq6
— Peter Davis (@peter_brit) January 17, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 16, 2024
WEBINAR ALERT
Fit-for-purpose matchmaking: A data selection and RWE approach for both regulatory and HTA audiences
February 15,Ā 2024Ā ā 10AMĀ EST; 3PMĀ GMT; 4PM CET
This webinar will review considerations for the design and data selection forā¦ pic.twitter.com/eAMjqLaZOM
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 16, 2024
Yup...suppression of COX2 in dendritic cells makes them work better in stimulating immunity.... Go $NWBO !! https://t.co/c5ZxCO30ZF
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 16, 2024
COX2 is increased in kidney cancer....wonder if this is a way in which it escapes from immune attack. Could COX2 inhibitors make dendritic cells like $NWBO work better? I mean they already work amazing https://t.co/gxPkv5zSl0
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 16, 2024
wow ! long noncoding RNA acting as tumor suppressor....very interesting how many diverse approaches the body uses to protect itself against #Cancer $NWBO is has generated the best #cancer killing sword to date...now we need to learn how toā¦ https://t.co/hZnflJtcag
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 16, 2024
Dont take oxytocin if you are taking dendritic cells.... this paper shows that the "love hormone" suppresses dendritic cell maturation....this could be a neat way of taking the $NWBO dendritic cells and flipping them for use im #autoimmunity. https://t.co/MPJwMO8s57
#dcvax #allsolidtumors $nwbo #gbm https://t.co/wweVzQ0r1a
— Peter Davis (@peter_brit) January 16, 2024
#dcvax #allsolidtumors $nwbo #gbm https://t.co/dP43vGL1AN
— Peter Davis (@peter_brit) January 16, 2024
In Magistrate Judge Stein's defense, I would add that Posner could have been more specific with her cite to the Milgrom Report in the Amended Complaint. She cited to where you could find the expert report but it was a docket that included hundreds of entries. See Image 1. In theā¦ pic.twitter.com/YRmuJ8bDFB
— hoffmann6383 (@hoffmann6383) January 15, 2024
I might be wrong but thought it was a holiday day in US today for OTC markets ?